Nutriband Signs Letter of Intent with Qvanta Group
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2025
0mins
Nutriband announced the signing of a non-binding Letter of Intent with the Qvanta Group of Companies. The Qvanta Group comprises Qvanta and its subsidiaries, Qvanta Foundry and Qvanta Capital. Qvanta is a U.S.-based advanced technology organization developing the Bigundefinedx Quantum Defense Fabric, an integrated quantum-AI cybersecurity and computing platform designed to support enterprise, government, and high-security research environments. The announcement comes amid heightened federal focus on three converging national priorities. On December 15, 2025 President Trump signed an Executive Order designating illicit fentanyl as a Weapon of Mass Destruction, recognizing the substance as a direct threat to U.S. national security. Nutriband believes that Qvanta's quantum-AI simulation capabilities, secure high-performance computing infrastructure, and advanced cybersecurity technologies may provide meaningful support for Nutriband's research, innovation efforts, and long-term product development initiatives.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on NTRB
Wall Street analysts forecast NTRB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRB is 15.00 USD with a low forecast of 15.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.700
Low
15.00
Averages
15.00
High
15.00
Current: 4.700
Low
15.00
Averages
15.00
High
15.00
No data
About NTRB
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Shareholder Value Enhancement: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M will add $5M to its bottom line without diluting existing shareholders, demonstrating the company's commitment to shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, thereby enhancing shareholder returns and loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying the groundwork for future commercialization, showcasing its technological edge in drug safety.
- Market Expansion: Nutriband's inclusion in four major indexes, including Russell Microcap and Russell 3000E, enhances its market visibility and investment appeal, potentially attracting more investors to its future growth prospects.
Continue Reading
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Enhanced Shareholder Value: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M is expected to add $5M to the bottom line without diluting shareholders, demonstrating the company's commitment to maximizing shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, which further enhances returns for investors and strengthens shareholder loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying a solid foundation for future commercialization, showcasing the company's innovative capabilities in drug safety technology.
- Index Inclusion Expansion: In 2025, Nutriband was added to four major indexes, including the Russell Microcap and Russell 3000E, which enhances the company's market visibility and investor interest, likely attracting more attention from potential investors.
Continue Reading